Multiple Ascending Dose Study in Healthy Subjects

A Phase 1 Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of NPT189 in Healthy Subjects

This will be a Phase 1, randomized, double-blind, single center, placebo-controlled, multiple ascending dose (MAD) study in a maximum of 3 cohorts of 8 healthy male and female subjects each. Subjects in Cohorts 1, 2 and 3 will receive ascending multiple IV doses of NPT189 or matching placebo.

Study Overview

• Status: Terminated
• Conditions: Amyloidosis
• Intervention / Treatment: Drug: NPT189

Detailed Description

This study is a Phase 1, randomized, double-blind, placebo-controlled, multiple dose, dose escalation safety, tolerability and PK study of NPT189 in healthy subjects. Three dose cohorts are planned each with a maximum of 8 subjects (6 active: 2 placebo) enrolled per cohort. Eligible subjects will be administered NPT189 by IV infusions at the dose specified for their cohort (i.e., 2 mg/kg, 5 mg/kg, and 12.5 mg/kg) or a matching placebo. Subjects will receive a total of 5 doses of NPT189, with doses administered at weekly intervals. Safety and tolerability will be assessed by analysis of adverse events (AEs), vital signs, electrocardiograms (ECG), laboratory and physical examinations. PK will be assessed by analysis of serum NPT189 concentrations.

• Study Type: Interventional
• Enrollment (Actual): 8
• Phase: Phase 1

Contacts and Locations

Study Locations

• Netherlands
  • Groningen, Netherlands, 9728 NZ
    • PRA Health Sciences

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 65 years (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. Age 18-65 years, inclusive, at screening
2. Weight 45-120 kg, inclusive
3. Body Mass Index of 18.0-32.0 kg/m2, inclusive
4. Female subjects of childbearing potential (defined as not surgically sterile or at least 2 years postmenopausal confirmed by a Screening Follicular Stimulating Hormone level of > 40) must agree to use two of the following forms of contraception from 60 days prior through 90 days following the dose of study drug: hormonal (oral, transdermal, implant, or injection), barrier (condom, diaphragm with spermicide), IUD, complete abstinence, or vasectomized partner (6 months minimum) or male subjects who are sexually active with women of childbearing potential must agree to complete abstinence or to use a condom for 90 days following the dose of study drug.
5. No clinically significant abnormal findings on physical examination, vital signs, electrocardiogram (ECG), or clinical laboratory evaluation during screening; and systolic blood pressure between 140 mm and 90 mm Hg and diastolic blood pressure between 90 mm and 45 mm Hg.
6. Can understand and sign the informed consent document, can communicate with the Investigator, and can understand and comply with the requirements of the protocol.

Exclusion Criteria:

1. Have a past or present serious medical illness or other medical or social reason that in the opinion of the Principal Investigator, would jeopardize the safety of the subject or impact the validity of the study results.
2. Participation in a clinical trial (other than a screening visit) within 60 days of study drug administration.
3. Use of any over-the-counter or prescription medication , vitamin preparations and other food supplements, or herbal medications (e.g., St. John's Wort) within 14 days prior to the dose of study drug or during the study, with the exception of hormonal contraceptives for women of childbearing potential, unless approved by the Principal Investigator or use of beta-blockers within 30 days prior to dose of study drug or during the study.
4. Donation of blood or plasma within 30 days of the dose of study drug and throughout the duration of the study and for male subjects, donation of sperm through the duration of the study.
5. Women who are nursing, pregnant, suspected of being pregnant, or trying to become pregnant, or are lactating, have a positive serum pregnancy test at screening or urine pregnancy test prior to administration of study drug regardless of childbearing potential.
6. Positive blood screen for HIV, hepatitis B surface antigen (HbSAg), or hepatitis C as Screening, or a positive urine screen for alcohol (the day before each dose administration only) or, drugs of abuse, or cotinine at Screening and on the day before each dose administration.
7. Have clinically significant abnormalities in laboratory values as judged by the clinical investigator.
8. Have a history of alcoholism and/or drug abuse.
9. Unsuitable veins for infusion or blood sampling.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: TREATMENT
• Allocation: RANDOMIZED
• Interventional Model: PARALLEL
• Masking: TRIPLE

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
OTHER: Treatment 2 mg/kg; Five IV doses of 2 mg/kg NPT189 (n = 6) or matching placebo (n = 2) administered once per week	Drug: NPT189; NPT189 is a recombinant immunoglobulin Fc fusion of GAIM (GAIM-IgG1Fc) as a potential treatment for peripheral amyloidosis.; Other Names: IgG1 (Immunoglobulin G); Fusion Protein; GAIM (General Amyloid Interaction Motif)
OTHER: Treatment 5 mg/kg; Five IV doses of 5 mg/kg NPT189 (n = 6) or matching placebo (n = 2) administered once per week	Drug: NPT189; NPT189 is a recombinant immunoglobulin Fc fusion of GAIM (GAIM-IgG1Fc) as a potential treatment for peripheral amyloidosis.; Other Names: IgG1 (Immunoglobulin G); Fusion Protein; GAIM (General Amyloid Interaction Motif)
OTHER: Treatment 12.5 mg/kg; Five IV doses of 12.5 mg/kg NPT189 (n = 6) or matching placebo (n = 2) administered once per week	Drug: NPT189; NPT189 is a recombinant immunoglobulin Fc fusion of GAIM (GAIM-IgG1Fc) as a potential treatment for peripheral amyloidosis.; Other Names: IgG1 (Immunoglobulin G); Fusion Protein; GAIM (General Amyloid Interaction Motif)

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Adverse event assessment in subjects receiving multiple intravenous infusions of NPT189	Summary of the frequency and percentage of adverse events	Day 1 through Day 112

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Profile of pharmacokinetics (PK) of multiple intravenous (IV) infusions of NPT189 (Cmax)	Observed maximum concentration (Cmax)	Day 1 through Day 112
Profile of pharmacokinetics (PK) of multiple intravenous (IV) infusions of NPT189 (Tmax)	Time of the maximum measured concentration (Tmax)	Day 1 through Day 112
Profile of pharmacokinetics (PK) of multiple (IV) infusions of NPT189 (AUC 0-tau)	Area under the serum concentration-time curve over a dosing interval, tau	Day 1 through Day 112
Profile of pharmacokinetics (PK) of multiple intravenous (IV) infusions of NPT189. Terminal elimination half-life (t 1/2)	Terminal elimination half-life (t 1/2)	Day 1 through DAy 112
Profile of pharmacokinetics (PK) of multiple (IV) infusions of NPT189. Clearance (CL)	Clearance (CL)	Day 1 through Day 112
Profile of pharmacokinetics (PK) of multiple (IV) infusions of NPT189. Volume of distribution (Vd)	Apparent volume of distribution (Vd)	Day 1 through Day 112

Collaborators and Investigators

• Sponsor: Proclara Biosciences, Inc.
• Investigators: Study Director: Proclara Biosciences, Inc, Proclara Biosciences

Study record dates

Study Major Dates

• Study Start (ACTUAL): March 6, 2019
• Primary Completion (ACTUAL): June 27, 2019
• Study Completion (ACTUAL): June 27, 2019

Study Registration Dates

• First Submitted: March 12, 2019
• First Submitted That Met QC Criteria: March 15, 2019
• First Posted (ACTUAL): March 18, 2019

Study Record Updates

• Last Update Posted (ACTUAL): August 19, 2019
• Last Update Submitted That Met QC Criteria: August 14, 2019
• Last Verified: March 1, 2019

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Metabolic Diseases; Proteostasis Deficiencies; Amyloidosis; Physiological Effects of Drugs; Immunologic Factors; Immunoglobulins; Immunoglobulin G
• Other Study ID Numbers: NPT189-CL002

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No